Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP. VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) is a small-molecule, selective, noncompetitive inhibitor directed against human IMPDH. In this report, we show that VX-944 inhibits in vitro growth of human multiple myeloma (MM) cell lines via induction of apoptosis. Interleukin-6, insulin-like growth factor-1, or co-culture with bone marrow stromal cells (BMSCs) do not protect against VX-944-induced MM cell growth inhibition. VX-944 induced apoptosis in MM cell lines with only modest activation of caspases 3, 8, and 9. Furthermore, the pan-caspase inhibitor z-VAD-fmk did not inhibit VX-944-induced apoptosis and cell death. During VX-944-induced apoptosis, expressions of Bax and Bak were enhanced, and both apoptosisinducing factor (AIF) and endonuclease G (Endo G) were released from the mitochondria to cytosol, suggesting that VX-944 triggers apoptosis in MM cells primarily via a caspase-independent, Bax/AIF/Endo G pathway. Importantly, VX-944 augments the cytotoxicity of doxorubicin and melphalan even in the presence of BMSCs. Taken together, our data demonstrate a primarily non-caspasedependent apoptotic pathway triggered by VX-944, thereby providing a rationale to enhance MM cell cytotoxicity by combining this agent with conventional agents which trigger caspase activation.
Introduction
Multiple myeloma (MM) remains incurable despite conventional therapies including high-dose chemotherapy with stem cell support. Importantly, novel agents like thalidomide, the immunomodulatory drug Revlimid, and the proteasome inhibitor bortezomib can achieve responses in patients with relapsed and refractory MM, and are now under evaluation as treatment for patients earlier in their disease course (Richardson et al., , 2003 (Richardson et al., , 2004 . Nonetheless, there remains an urgent need for the development of new therapeutic strategies for MM treatment.
Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP (Zimmermann et al., 1998) . There are two IMPDH isoforms in mammalian cells: type I is constitutively expressed in most cell types, and catalytically similar type II is activated in proliferating cells (Nagai et al., 1991; Senda and Natsumeda, 1994) . Gene expression of IMPDH type II is elevated in patient MM cells compared with normal control plasma cells (Takebe et al., 2004) . Conversely, inhibition of IMPDH induces depletion of guanine nucleotide pools, followed by decreased DNA and RNA synthesis . Recently, IMPDH has been shown to bind nucleic acids in vitro and in vivo, suggesting that it may have a direct role in replication and transcription (McLean et al., 2004) . IMPDH inhibitors induce cell-cycle arrest and decrease T-and B-cell responses effectively, both in vitro and in vivo. Consequently, they have been evaluated primarily as immunosuppressive rather than anticancer therapies (Eugui and Almquist, 1990; Eugui et al., 1991; Turka et al., 1991; Jain et al., 2001) . Specifically, the IMPDH inhibitors benzamide riboside (BR) and mycophenolic acid (MPA) were found to induce growth inhibition, but not cytotoxicity, in the panel of 60 cancer cell lines derived from hematological and solid tumors at the National Cancer Institute (http://dtp.nci.nih.gov). More recently, however, BR and MPA have been shown to induce apoptosis in selected cancer cells (Hunakova et al., 2000; Szekeres et al., 2002; Messina et al., 2004) . Although activation of caspases and inhibition of PARP have been reported as possible mediators of apoptosis triggered by MPA and BR Gu et al., 2003) , their mechanisms of action are not fully characterized. MPA and tiazofurin, another IMPDH inhibitor, have been evaluated in cancer animal models (Sweeney et al., 1972; Ahluwalia et al., 1984) , as well as in clinical trials, for the treatment of leukemia and CML, respectively (Knudtzon and Nissen, 1972; Wright et al., 1996) . Both compounds showed some objective responses, but gastrointestinal intolerance (MPA) or neurotoxicity (tiazofurin) has limited further investigation. Hence, evaluation of more selective and well-tolerated IMPDH inhibitors is needed to determine the therapeutic potential of this approach in the treatment of malignancy.
VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) is a small-molecule, selective, noncompetitive inhibitor of both human IMPDH isoforms (Ki 6-10 nM). In this study, we evaluated the cytotoxicity of VX-944 against MM cells in vitro. We demonstrate that VX-944 inhibits growth of MM cell lines by induction of apoptosis, primarily via a caspase-independent pathway.
Results

VX-944 inhibits growth of MM cell lines
The effect of VX-944 on growth of MM cell lines was determined using the MTT assay. VX-944 significantly inhibited the growth of RPMI8226, MM.1S, and U266 cells in a dose-dependent fashion, with 50% inhibition (IC 50 (Figure 1a ). The degree of growth inhibition at 72 h was observed to be similar to that at 48 h. The effects of VX-944 on DNA synthesis were also determined by measuring [ 3 H]thymidine incorporation during the last 8 h of 48-h cultures. IC 50 values determined by this method were lower than those determined in the MTT assay: 350 nM for RPMI8226, 100 nM for MM.1S and 75 nM for U266 cells (data not shown). Growth inhibition induced by VX-944 is significantly reversed by the addition of guanosine, which is converted to guanine and thereby circumvents the effect of inhibition of IMPDH on guanine nucleotide levels (Zimmermann et al., 1998) (Figure 1b) . Importantly, VX-944 did not reduce the viability of peripheral blood mononuclear cells (PBMNCs) derived from healthy individuals at 48 h at concentrations up to 6400 nM (Figure 1c ). This is consistent with the expression of type II IMPDH, which is lower in normal lymphocytes as compared to cancer cells. Increased expression of type II isoform has been closely linked with an increase in total IMPDH activity in cancer cells (Nagai et al., 1991) . 
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We next examined the apoptotic pathway induced by VX-944. Cleavage of caspase-8, -9, and -3 triggered by VX-944 in MM.1S and RPMI8226 cells was modest, and there was no cleavage of DFF45 (Figure 3a ).
Caspases 6 and 7, mediators of caspase 3-independent apoptosis (Miyashita et al., 1998; Kagawa et al., 2001; Pirnia et al., 2002) , were not activated by VX-944 (data not shown). To further confirm caspase-independent 
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K Ishitsuka et al apoptosis, the effects of z-VAD-fmk on cytotoxicity and apoptosis induced by VX-944 were next determined. Z-VAD-fmk is a broad-specificity caspase inhibitor with second-order inactivation rates; 7100, 16 000, 18 000, 180 000, 280 000 M À1 s À1 for caspases 6, 3, 7, 9, and 8, respectively (Garcia-Calvo et al., 1998) . MM.1S cells (3 Â 10 5 /ml) and RPMI8226 cells (1.5 Â 10 5 /ml) were exposed to 800 nM VX-944 for 48 h, with or without z-VAD-fmk (25 mM) pretreatment for 2 h. Neither growth inhibition nor cytotoxicity of VX-944, as determined by trypan blue exclusion, was reduced by pretreatment with z-VAD-fmk (Figure 3b ). Cytotoxicity of lower concentrations of VX-944 (200 and 400 nM) was similarly unaffected by pretreatment with z-VAD-fmk (data not shown). Moreover, pretreatment with z-VAD-fmk did not block induction of apoptosis (Figure 3c ). MM.1S cells treated with arsenic trioxide (As 2 O 3 ; 4 mM) for 48 h, with or without z-VAD-fmk pretreatment, were a control for caspase-dependent apoptosis and the inhibitory activity of z-VAD-fmk (Hayashi et al., 2002; McCafferty-Grad et al., 2003) .
Modulation of pro-and anti-apoptotic proteins by VX-944 was next evaluated. MM.1S and RPMI8226 cells were treated with 800 nM VX-944 for 12, 24, and 48 h; cell lysates were prepared as described previously. Of bcl-2 family member proteins, Bax and Bak were markedly upregulated in VX-944-treated cells, without significant changes in Bcl-2, Mcl-1, XIAP, and Bad (Figure 4a) . Furthermore, translocation of mitochondrial proapoptotic proteins, apoptosis-inducing factor (AIF) and endonuclease G (Endo G) to cytosolic fractions was observed (Figure 4b ).
Effect of VX-944 on MM cells cultured with exogenous IL-6, IGF-1, and bone marrow stromal cells (BMSCs)
We next examined the effect of VX-944 on MM cells in the presence of exogenous IL-6 and IGF-1, as well as on MM cell growth in the BM microenvironment. Neither IL-6 nor IGF-1 protected against VX-944-induced growth inhibition (Figure 5a and b) . Binding of Caspases are believed to be the key executors of apoptosis. However, recent studies suggest that caspase activation is not the sole pathway for inducing apoptosis or necrosis by death stimuli (Jaattela and Tschopp, 2003; Abraham and Shaham, 2004; Lockshin and Zakeri, 2004) . For example, caspase-independent cell death in MM cells has been reported in As 2 O 3 -treated RPMI8226 cells and patient MM cells (McCaffertyGrad et al., 2003) . Since most drugs used to treat MM induce cell death via activation of caspases, agents such as VX-944 that can kill MM cells via caspaseindependent pathways may be particularly useful for combination with conventional and novel drugs to overcome drug resistances.
During VX-944-induced apoptosis, activation of caspases 3, 8 and 9 was only modest; caspases 6 and 7, known mediators of caspase 3-independent apoptotic signaling (Miyashita et al., 1998; Kagawa et al., 2001; Pirnia et al., 2002) , were not activated. Cleavage of DFF45, which inactivates the inhibitory function of DFF40 and related nuclear DNA fragmentation (Liu et al., 1998) , was not observed. In addition, pretreatment with z-VAD did not significantly inhibit VX-944 triggered cytotoxicity or apoptosis. Therefore, VX-944 appears to induce apoptosis primarily via a caspaseindependent mechanism.
We next determined whether VX-944 induced Bax and Bak protein expression, as well as translocation of AIF and Endo G to the cytoplasm. The Bax/AIF/Endo G pathway is a major caspase-independent apoptotic cascade (Daugas et al., 2000; Ahn et al., 2004; Cande et al., 2004; Cregan et al., 2004) . In this pathway, enhanced Bax and Bak expression induces mitochondrial membrane permeabilization, thereby releasing AIF and Endo G from the mitochondria to the cytosol and nucleus, with subsequent chromatin condensation and cell death. Conversely, reports that apoptosis induced via Bax/AIF/Endo G pathway can be caspase-dependent show that the release of AIF and Endo G from mitochondria is blocked by z-VAD (Arnoult et al., 2003; Cande et al., 2004) . In our study, the release of these proapoptotic proteins is likely caspase-independent, since caspase activation was modest.
As most conventional and novel drugs induce apoptosis in MM cells via activation of caspases, agents killing MM cells via caspase-independent pathways may overcome drug resistances. Therefore, we next examined the effect of combining VX-944 and other drugs in vitro. The additive effect of VX-944 and Dox or Mel shown in our study indicates that VX-944 can be combined with these drugs to enhance their efficacy. Sequential treatment with VX-944, followed by Dox or Mel, holds great promise, since these combinations inhibited the growth of MM cells even in the presence of BMSCs.
In conclusion, we have shown that the novel IMPDH inhibitor VX-944 appears to induce apoptosis mainly via a caspase-independent, Bax/AIF/Endo G pathway in MM cells. VX-944 induces cell death in drug-resistant MM cells and overcomes the growth-promoting activity of IL-6, IGF-1 and BMSCs. These results suggest that VX-944, used either alone or in combination with other drugs, represents a promising novel targeted approach to enhance MM cell cytotoxicity and improve patient outcome in MM.
Materials and methods
Cells
Dex-sensitive MM.1S and Dex-resistant MM.1R human MM cell lines were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). RPMI 8226-Dox40 (Dox-resistant) and RPMI 8226-LR5 (Mel-resistant) human MM cell lines were kindly provided by Dr William Dalton (Moffit Cancer Center, Tampa, FL, USA). RPMI-8226 and U266 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Fresh PBMNCs obtained from three healthy subjects after informed consent were separated from heparinized peripheral blood by FicollHipaque density sedimentation. Cells were cultured at 371C in RPMI 1640 containing 10% fetal bovine serum (FBS; Sigma, St Louis, MO, USA), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (Gibco, Grand Island, NY, USA).
MNCs in BM specimens, obtained from patients with MM after informed consent, were separated by Ficoll-Hipaque density sedimentation and used to establish long-term BMSC cultures, as described (Uchiyama et al., 1993; Hideshima et al., 2001) .
Reagents VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) was dissolved in dimethyl sulfoxide (DMSO) at 10 mM stock solution and stocked at À201C. Guanosine and Dox (Sigma, St Louis, MO, USA) were dissolved in sterile water at 1 and 3.45 mM, respectively. Mel (Sigma, St Louis, MO, USA) was dissolved in DMSO at 20 mM. Recombinant human IL-6 and IGF-1 (R&D Systems, Minneapolis, MN, USA) were reconstituted with sterile PBS containing 0.1% FBS and 10 mM acetic acid containing 0.1% FBS, respectively. Pan-caspase inhibitor z-VAD-fmk (Bachem, Bubendorf, Switzerland) was dissolved in methanol.
Cellular proliferation and DNA synthesis assay
Colorimetric assays were performed to evaluate drug activity. MM cell lines and MM patient BMSCs were cultured in 96-well culture plates with VX-944 in 100 ml of media for 48 h, pulsed with 10 ml of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Sigma, St Louis, MO, USA) to each well for 4 h, followed by 100 ml isopropanol containing 0.04 N HCl. Absorbance readings at a wavelength of 570 nm and reference wave length of 630 nm were taken on a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA, USA).
DNA synthesis was measured by [ (Perkin-Elmer, Boston, MA, USA) during the last 8 h of culture, harvested onto glass filters with an automatic cell harvester (Cambridge Technology, Cambridge, MA, USA), and counted using the LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD, USA). All experiments were performed in triplicate.
Detection of cytotoxicity and apoptosis
Cytotoxicity was determined by trypan blue exclusion assay (Sigma, St Louis, MO, USA). Viability was expressed as percent viable cells. Apoptosis in VX-944-treated cells was assesed by annexin V and PI staining, TUNEL assay, and APO 2.7 staining. For annexin V and PI staining, cells were suspended in binding buffer (10 mmol/l HEPES, pH 7.4, 140 mmol/l NaCl, 2.5 mmol/l CaCl 2 ), followed by incubation with annexin V-FITC (MBL, Nagoya, Japan) and PI (MBL, Nagoya, Japan) for 5 min at room temperature. To detect DNA strand breaks, the TUNEL assay was performed using a commercial kit (MBL, Nagoya, Japan). In brief, cells were fixed and permeabilized by 4% paraformaldehyde and 70% ethanol, followed by incubation with a mixture of FITC-dUTP and TdT for 1 h at 371C. For detection of mitochondrial membrane protein 7A6 expressed in apoptotic cells, cells were incubated with APO 2.7 reagent (Immunotech, Marseille, France) for 20 min. Expression of Annexin V and PI, TUNEL, and APO 2.7 was determined using an EPICS XL flow cytometer.
Western blotting
MM cells were harvested, washed twice with ice-cold PBS, and lysed in lysis buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM NaF, 2 mM Na 3 V 4 , 1 mM PMSF, 5 mg/ml leupeptine, and 5 mg/ml aprotinin after VX-944 treatment. Subcellular proteins were extracted from 2 Â 10 7 viable cells using mitochondria isolation kit (Pierce, Rockford, IL, USA). Whole-cell lysates or fractionated proteins were subjected to SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with anti-caspase-3, caspase-6, caspase-7, caspase-8, caspase-9, DFF45/35, Bax, Bak, XIAP, 
